Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dalfampridine
Drug ID BADD_D00574
Description Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Indications and Usage Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
Marketing Status approved
ATC Code N07XX07
DrugBank ID DB06637
KEGG ID D04127
MeSH ID D015761
PubChem ID 1727
TTD Drug ID D08YIN
NDC Product Code 10144-427; 63190-0510; 67877-444; 56125-427; 0591-2533; 65862-917; 62756-429; 63629-9450; 65862-863; 38779-3205; 42571-338; 51927-5030; 42571-275; 0378-4504; 12817-054; 46016-5042; 54382-125; 62756-038; 62991-3143; 65372-1157; 16729-292; 63190-0530; 51407-246; 0054-0479
UNII BH3B64OKL9
Synonyms 4-Aminopyridine | 4 Aminopyridine | Dalfampridine | Pymadine | VMI-103 | VMI 103 | VMI103 | 4-Aminopyridine Sustained Release | 4 Aminopyridine Sustained Release | Sustained Release, 4-Aminopyridine | Fampridine-SR | Fampridine SR
Chemical Information
Molecular Formula C5H6N2
CAS Registry Number 504-24-5
SMILES C1=CN=CC=C1N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gallbladder disorder09.03.02.0010.001077%-
Gastrointestinal disorder07.11.01.001---
Generalised tonic-clonic seizure17.12.01.0020.003230%-
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.0470.005383%
Headache17.14.01.0010.110415%
Hemiparesis17.01.04.0010.003015%
Hemiplegia17.01.04.0020.000538%-
Hunger08.01.09.003; 14.03.02.0120.000538%-
Hyperreflexia17.02.01.0020.001184%-
Hypersensitivity10.01.03.0030.022772%
Hypersomnia17.15.01.001; 19.02.05.0010.005114%
Hyperventilation19.01.02.004; 22.02.01.0060.000538%-
Hypoaesthesia17.02.06.023; 23.03.03.0810.029878%-
Hypokinesia17.01.02.0090.007214%-
Hypotension24.06.03.002--
Immune system disorder10.02.01.0010.001184%-
Incontinence07.01.06.011; 17.05.01.006; 20.02.02.0040.005922%-
Infection11.01.08.002---
Influenza like illness08.01.03.0100.005383%
Ingrowing nail23.02.05.0110.001830%-
Initial insomnia17.15.03.005; 19.02.01.0050.002100%-
Injection site bruising08.02.03.042; 12.07.03.042; 23.03.11.015; 24.07.06.0170.001830%-
Injection site erythema08.02.03.001; 12.07.03.001; 23.03.06.0150.002746%-
Injection site haematoma08.02.03.004; 12.07.03.004; 24.07.01.0090.001184%-
Injection site haemorrhage08.02.03.005; 12.07.03.005; 24.07.01.0100.000538%-
Injection site induration08.02.03.007; 12.07.03.0070.001184%-
Injection site mass08.02.03.009; 12.07.03.0100.003930%-
Injection site pain08.02.03.010; 12.07.03.0110.005653%-
Injection site reaction08.02.03.014; 12.07.03.0150.001184%
Injection site vesicles08.02.03.051; 12.07.03.051; 23.03.01.0240.001830%-
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages